Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

Propranolol, a pleiotropic β-adrenergic blocker, has been anecdotally reported to reduce cerebral cavernous malformations (CCMs) in humans. However, propranolol has not been rigorously evaluated in animal models, nor has its mechanism of action in CCM been defined. We report that propranolol or its...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Invest
Главные авторы: Li, Wenqing, Shenkar, Robert, Detter, Mathew R., Moore, Thomas, Benavides, Christian, Lightle, Rhonda, Girard, Romuald, Hobson, Nicholas, Cao, Ying, Li, Yan, Griffin, Erin, Gallione, Carol, Zabramski, Joseph M., Ginsberg, Mark H., Marchuk, Douglas A., Awad, Issam A.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2021
Предметы:
Concise Communication
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843213/
https://ncbi.nlm.nih.gov/pubmed/33301422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI144893
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы